Get started
Author

Oleksandr Dudnichenko

Observed names: O. S. Dudnichenko, O.S. Dudnichenko
ORCID: 0000-0001-8626-8435
Observed ORCID: 0000-0001-8626-8435
OpenAlex ID: A5044392466
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
2023 · Philip Clingan, Rahul Ladwa, et al. · Journal for ImmunoTherapy of Cancer · 63
PDF
Abstract GS01-05: Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study
2024 · Hope Rugo, Mark Robson, et al. · Cancer Research · 23
First-line encorafenib plus binimetinib and pembrolizumab for advanced BRAF V600-mutant melanoma: Safety lead-in results from the randomized phase III STARBOARD study
2024 · Oleksandr Dudnichenko, Konstantin Penkov, et al. · European Journal of Cancer · 13
PDF
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy
2025 · Hope S. Rugo, David W. Cescon, et al. · Clinical Cancer Research · 11
A single-center, cohort study of the mutational profile of Ukrainian patients with non-small cell lung cancer
2024 · O.I. Vynnychenko, Y.V. Moskalenko, et al. · Український радіологічний та онкологічний журнал · 1
PDF
The long-term results of using free and liposomal doxorubicin in children with solid tumours
2017 · V. E. Bіletskyi, O. S. Dudnichenko · Problems of Uninterrupted Medical Training and Science · 1
The Impact of Cannabis and Medical Use of Cannabis in Surgical Practice: a Narrative Review
2026 · Artem Riga, Oleksandr Dudnichenko, et al. · Eastern Ukrainian Medical Journal
PDF
Rechallenge or switching to other CDK4/6 inhibitors in HR+/HER2–metastatic breast cancer after progression
2026 · O.S. Dudnichenko, B.S. Khilchevskyi, et al. · Український радіологічний та онкологічний журнал
PDF
Supplementary Figure S2 from KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy
2026 · Hope S. Rugo, David W. Cescon, et al.
Supplementary Table S1 from KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy
2026 · Hope S. Rugo, David W. Cescon, et al.
Supplementary Figure S1 from KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy
2026 · Hope S. Rugo, David W. Cescon, et al.
Supplementary Table S2 from KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy
2026 · Hope S. Rugo, David W. Cescon, et al.
Supplementary Table S3 from KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy
2026 · Hope S. Rugo, David W. Cescon, et al.
Data from KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy
2026 · Hope S. Rugo, David W. Cescon, et al.
A plain language summary of the preliminary results for encorafenib plus binimetinib and pembrolizumab in adults with BRAF V600-mutant melanoma in the STARBOARD study
2025 · Oleksandr Dudnichenko, Konstantin Penkov, et al. · Future Oncology
PDF
The expression of topoisomerase IIΑ as a prognostic marker in patients with primary breast cancer
2017 · D. E. Ryspayeva, I. I. Smolanka, et al. · Problems of Uninterrupted Medical Training and Science
Works count: 16
Citation count: 112
H-index: 4
I10-index: 4
Year
Topic
Type